Www.dovepress.com



TOC \h \z \c "Supplemental table" Supplemental table 1: Definitions of CHA2DS2VASc and HAS-BLED scores PAGEREF _Toc44571325 \h 2Supplemental table 2: Other anticoagulants specified according to ATC codes PAGEREF _Toc44571326 \h 3Supplemental table 3: Definition of covariates according to International Classification of Diseases 10th version codes and the Anatomic Therapeutic Chemical classification system. PAGEREF _Toc44571327 \h 4Supplemental table 4: Definition of studied outcomes according to ICD 10 codes PAGEREF _Toc44571328 \h 5Supplemental table 5: Standardized difference as the differences in means between each pair of treatment groups divided by the standard deviation, before and after propensity score PAGEREF _Toc44571329 \h 7Supplemental table 6: Hazard ratios with 95% confidence intervals, for each outcome and comparison, by sex. All patients were 60 years of age or older and with a diagnosis of atrial fibrillation within 6 months before start of treatment with direct thrombin inhibitors, direct factor Xa inhibitors or with vitamin K antagonists PAGEREF _Toc44571330 \h 10Supplemental table 7: Hazard ratios with 95% confidence intervals, for each outcome and comparison, by age. All patients were 60 years of age or older and with a diagnosis of atrial fibrillation within 6 months before start of treatment with direct thrombin inhibitors, direct factor Xa inhibitors or with vitamin K antagonists PAGEREF _Toc44571331 \h 10Supplemental table 8: Hazard ratios with 95% confidence intervals, for each outcome and comparison, by user status. All patients were 60 years of age or older and with a diagnosis of atrial fibrillation within 6 months before start of treatment with direct thrombin inhibitors, direct factor Xa inhibitors or with vitamin K antagonists PAGEREF _Toc44571332 \h 11Supplemental table SEQ Supplemental_table \* ARABIC 1: Definitions of CHA2DS2VASc and HAS-BLED scoresRisk scorePoints if present*CHA2DS2VAScCongestive heart failure1Hypertension1Age ≥ 65 years1Age ≥ 75 years1Diabetes1Stroke (ischemic stroke Transient ischemic attack or systemic embolism)2Vascular disease 1Sex (female)1?HAS-BLEDHypertension1Abnormal renal function1Abnormal hepatic function1Stroke (ischemic stroke Transient ischemic attack)1Bleedings1Age ≥ 65 years1Medicines (aspirin, clopidogrel or non-steroidal anti-inflammatory)1Alcohol intake1Labile international normalized ratio (not available in our study)1*Reflects stroke risk in atrial fibrillation patients not in anticoagulant therapy, according to Lip et al 2010PEVuZE5vdGU+PENpdGU+PEF1dGhvcj5MaXA8L0F1dGhvcj48WWVhcj4yMDEwPC9ZZWFyPjxSZWNO

dW0+ODwvUmVjTnVtPjxEaXNwbGF5VGV4dD48c3R5bGUgZmFjZT0ic3VwZXJzY3JpcHQiPjI1PC9z

dHlsZT48L0Rpc3BsYXlUZXh0PjxyZWNvcmQ+PHJlYy1udW1iZXI+ODwvcmVjLW51bWJlcj48Zm9y

ZWlnbi1rZXlzPjxrZXkgYXBwPSJFTiIgZGItaWQ9InRleHBlZGR0bWZlZHBzZWZ3Zm81ZnphY3d6

YTlhdmZyeGZkYSIgdGltZXN0YW1wPSIxNDE2NTcyNzgwIj44PC9rZXk+PC9mb3JlaWduLWtleXM+

PHJlZi10eXBlIG5hbWU9IkpvdXJuYWwgQXJ0aWNsZSI+MTc8L3JlZi10eXBlPjxjb250cmlidXRv

cnM+PGF1dGhvcnM+PGF1dGhvcj5MaXAsIEcuIFkuPC9hdXRob3I+PGF1dGhvcj5OaWV1d2xhYXQs

IFIuPC9hdXRob3I+PGF1dGhvcj5QaXN0ZXJzLCBSLjwvYXV0aG9yPjxhdXRob3I+TGFuZSwgRC4g

QS48L2F1dGhvcj48YXV0aG9yPkNyaWpucywgSC4gSi48L2F1dGhvcj48L2F1dGhvcnM+PC9jb250

cmlidXRvcnM+PGF1dGgtYWRkcmVzcz5Vbml2ZXJzaXR5IG9mIEJpcm1pbmdoYW0gQ2VudHJlIGZv

ciBDYXJkaW92YXNjdWxhciBTY2llbmNlcywgQ2l0eSBIb3NwaXRhbCwgQmlybWluZ2hhbSwgVUsu

IGcueS5oLmxpcEBiaGFtLmFjLnVrPC9hdXRoLWFkZHJlc3M+PHRpdGxlcz48dGl0bGU+UmVmaW5p

bmcgY2xpbmljYWwgcmlzayBzdHJhdGlmaWNhdGlvbiBmb3IgcHJlZGljdGluZyBzdHJva2UgYW5k

IHRocm9tYm9lbWJvbGlzbSBpbiBhdHJpYWwgZmlicmlsbGF0aW9uIHVzaW5nIGEgbm92ZWwgcmlz

ayBmYWN0b3ItYmFzZWQgYXBwcm9hY2g6IHRoZSBldXJvIGhlYXJ0IHN1cnZleSBvbiBhdHJpYWwg

ZmlicmlsbGF0aW9uPC90aXRsZT48c2Vjb25kYXJ5LXRpdGxlPkNoZXN0PC9zZWNvbmRhcnktdGl0

bGU+PGFsdC10aXRsZT5DaGVzdDwvYWx0LXRpdGxlPjwvdGl0bGVzPjxwZXJpb2RpY2FsPjxmdWxs

LXRpdGxlPkNoZXN0PC9mdWxsLXRpdGxlPjxhYmJyLTE+Q2hlc3Q8L2FiYnItMT48L3BlcmlvZGlj

YWw+PGFsdC1wZXJpb2RpY2FsPjxmdWxsLXRpdGxlPkNoZXN0PC9mdWxsLXRpdGxlPjxhYmJyLTE+

Q2hlc3Q8L2FiYnItMT48L2FsdC1wZXJpb2RpY2FsPjxwYWdlcz4yNjMtNzI8L3BhZ2VzPjx2b2x1

bWU+MTM3PC92b2x1bWU+PG51bWJlcj4yPC9udW1iZXI+PGtleXdvcmRzPjxrZXl3b3JkPkFnZWQ8

L2tleXdvcmQ+PGtleXdvcmQ+QXRyaWFsIEZpYnJpbGxhdGlvbi8qY29tcGxpY2F0aW9ucy9lcGlk

ZW1pb2xvZ3k8L2tleXdvcmQ+PGtleXdvcmQ+RXVyb3BlL2VwaWRlbWlvbG9neTwva2V5d29yZD48

a2V5d29yZD5GZW1hbGU8L2tleXdvcmQ+PGtleXdvcmQ+Rm9sbG93LVVwIFN0dWRpZXM8L2tleXdv

cmQ+PGtleXdvcmQ+SHVtYW5zPC9rZXl3b3JkPjxrZXl3b3JkPkluY2lkZW5jZTwva2V5d29yZD48

a2V5d29yZD5NYWxlPC9rZXl3b3JkPjxrZXl3b3JkPlBvcHVsYXRpb24gU3VydmVpbGxhbmNlLypt

ZXRob2RzPC9rZXl3b3JkPjxrZXl3b3JkPlByb2dub3Npczwva2V5d29yZD48a2V5d29yZD5SZXBy

b2R1Y2liaWxpdHkgb2YgUmVzdWx0czwva2V5d29yZD48a2V5d29yZD5SZXRyb3NwZWN0aXZlIFN0

dWRpZXM8L2tleXdvcmQ+PGtleXdvcmQ+UmlzayBBc3Nlc3NtZW50LyptZXRob2RzPC9rZXl3b3Jk

PjxrZXl3b3JkPlJpc2sgRmFjdG9yczwva2V5d29yZD48a2V5d29yZD5TdHJva2UvKmVwaWRlbWlv

bG9neS9ldGlvbG9neTwva2V5d29yZD48a2V5d29yZD5UaHJvbWJvZW1ib2xpc20vKmVwaWRlbWlv

bG9neS9ldGlvbG9neTwva2V5d29yZD48L2tleXdvcmRzPjxkYXRlcz48eWVhcj4yMDEwPC95ZWFy

PjxwdWItZGF0ZXM+PGRhdGU+RmViPC9kYXRlPjwvcHViLWRhdGVzPjwvZGF0ZXM+PGlzYm4+MTkz

MS0zNTQzIChFbGVjdHJvbmljKSYjeEQ7MDAxMi0zNjkyIChMaW5raW5nKTwvaXNibj48YWNjZXNz

aW9uLW51bT4xOTc2MjU1MDwvYWNjZXNzaW9uLW51bT48dXJscz48cmVsYXRlZC11cmxzPjx1cmw+

aHR0cDovL3d3dy5uY2JpLm5sbS5uaWguZ292L3B1Ym1lZC8xOTc2MjU1MDwvdXJsPjx1cmw+aHR0

cDovL2pvdXJuYWwucHVibGljYXRpb25zLmNoZXN0bmV0Lm9yZy9kYXRhL0pvdXJuYWxzL0NIRVNU

LzIyMDgxL2NoZXN0LjA5LTE1ODQucGRmPC91cmw+PC9yZWxhdGVkLXVybHM+PC91cmxzPjxlbGVj

dHJvbmljLXJlc291cmNlLW51bT4xMC4xMzc4L2NoZXN0LjA5LTE1ODQ8L2VsZWN0cm9uaWMtcmVz

b3VyY2UtbnVtPjwvcmVjb3JkPjwvQ2l0ZT48L0VuZE5vdGU+AG==

ADDIN EN.CITE PEVuZE5vdGU+PENpdGU+PEF1dGhvcj5MaXA8L0F1dGhvcj48WWVhcj4yMDEwPC9ZZWFyPjxSZWNO

dW0+ODwvUmVjTnVtPjxEaXNwbGF5VGV4dD48c3R5bGUgZmFjZT0ic3VwZXJzY3JpcHQiPjI1PC9z

dHlsZT48L0Rpc3BsYXlUZXh0PjxyZWNvcmQ+PHJlYy1udW1iZXI+ODwvcmVjLW51bWJlcj48Zm9y

ZWlnbi1rZXlzPjxrZXkgYXBwPSJFTiIgZGItaWQ9InRleHBlZGR0bWZlZHBzZWZ3Zm81ZnphY3d6

YTlhdmZyeGZkYSIgdGltZXN0YW1wPSIxNDE2NTcyNzgwIj44PC9rZXk+PC9mb3JlaWduLWtleXM+

PHJlZi10eXBlIG5hbWU9IkpvdXJuYWwgQXJ0aWNsZSI+MTc8L3JlZi10eXBlPjxjb250cmlidXRv

cnM+PGF1dGhvcnM+PGF1dGhvcj5MaXAsIEcuIFkuPC9hdXRob3I+PGF1dGhvcj5OaWV1d2xhYXQs

IFIuPC9hdXRob3I+PGF1dGhvcj5QaXN0ZXJzLCBSLjwvYXV0aG9yPjxhdXRob3I+TGFuZSwgRC4g

QS48L2F1dGhvcj48YXV0aG9yPkNyaWpucywgSC4gSi48L2F1dGhvcj48L2F1dGhvcnM+PC9jb250

cmlidXRvcnM+PGF1dGgtYWRkcmVzcz5Vbml2ZXJzaXR5IG9mIEJpcm1pbmdoYW0gQ2VudHJlIGZv

ciBDYXJkaW92YXNjdWxhciBTY2llbmNlcywgQ2l0eSBIb3NwaXRhbCwgQmlybWluZ2hhbSwgVUsu

IGcueS5oLmxpcEBiaGFtLmFjLnVrPC9hdXRoLWFkZHJlc3M+PHRpdGxlcz48dGl0bGU+UmVmaW5p

bmcgY2xpbmljYWwgcmlzayBzdHJhdGlmaWNhdGlvbiBmb3IgcHJlZGljdGluZyBzdHJva2UgYW5k

IHRocm9tYm9lbWJvbGlzbSBpbiBhdHJpYWwgZmlicmlsbGF0aW9uIHVzaW5nIGEgbm92ZWwgcmlz

ayBmYWN0b3ItYmFzZWQgYXBwcm9hY2g6IHRoZSBldXJvIGhlYXJ0IHN1cnZleSBvbiBhdHJpYWwg

ZmlicmlsbGF0aW9uPC90aXRsZT48c2Vjb25kYXJ5LXRpdGxlPkNoZXN0PC9zZWNvbmRhcnktdGl0

bGU+PGFsdC10aXRsZT5DaGVzdDwvYWx0LXRpdGxlPjwvdGl0bGVzPjxwZXJpb2RpY2FsPjxmdWxs

LXRpdGxlPkNoZXN0PC9mdWxsLXRpdGxlPjxhYmJyLTE+Q2hlc3Q8L2FiYnItMT48L3BlcmlvZGlj

YWw+PGFsdC1wZXJpb2RpY2FsPjxmdWxsLXRpdGxlPkNoZXN0PC9mdWxsLXRpdGxlPjxhYmJyLTE+

Q2hlc3Q8L2FiYnItMT48L2FsdC1wZXJpb2RpY2FsPjxwYWdlcz4yNjMtNzI8L3BhZ2VzPjx2b2x1

bWU+MTM3PC92b2x1bWU+PG51bWJlcj4yPC9udW1iZXI+PGtleXdvcmRzPjxrZXl3b3JkPkFnZWQ8

L2tleXdvcmQ+PGtleXdvcmQ+QXRyaWFsIEZpYnJpbGxhdGlvbi8qY29tcGxpY2F0aW9ucy9lcGlk

ZW1pb2xvZ3k8L2tleXdvcmQ+PGtleXdvcmQ+RXVyb3BlL2VwaWRlbWlvbG9neTwva2V5d29yZD48

a2V5d29yZD5GZW1hbGU8L2tleXdvcmQ+PGtleXdvcmQ+Rm9sbG93LVVwIFN0dWRpZXM8L2tleXdv

cmQ+PGtleXdvcmQ+SHVtYW5zPC9rZXl3b3JkPjxrZXl3b3JkPkluY2lkZW5jZTwva2V5d29yZD48

a2V5d29yZD5NYWxlPC9rZXl3b3JkPjxrZXl3b3JkPlBvcHVsYXRpb24gU3VydmVpbGxhbmNlLypt

ZXRob2RzPC9rZXl3b3JkPjxrZXl3b3JkPlByb2dub3Npczwva2V5d29yZD48a2V5d29yZD5SZXBy

b2R1Y2liaWxpdHkgb2YgUmVzdWx0czwva2V5d29yZD48a2V5d29yZD5SZXRyb3NwZWN0aXZlIFN0

dWRpZXM8L2tleXdvcmQ+PGtleXdvcmQ+UmlzayBBc3Nlc3NtZW50LyptZXRob2RzPC9rZXl3b3Jk

PjxrZXl3b3JkPlJpc2sgRmFjdG9yczwva2V5d29yZD48a2V5d29yZD5TdHJva2UvKmVwaWRlbWlv

bG9neS9ldGlvbG9neTwva2V5d29yZD48a2V5d29yZD5UaHJvbWJvZW1ib2xpc20vKmVwaWRlbWlv

bG9neS9ldGlvbG9neTwva2V5d29yZD48L2tleXdvcmRzPjxkYXRlcz48eWVhcj4yMDEwPC95ZWFy

PjxwdWItZGF0ZXM+PGRhdGU+RmViPC9kYXRlPjwvcHViLWRhdGVzPjwvZGF0ZXM+PGlzYm4+MTkz

MS0zNTQzIChFbGVjdHJvbmljKSYjeEQ7MDAxMi0zNjkyIChMaW5raW5nKTwvaXNibj48YWNjZXNz

aW9uLW51bT4xOTc2MjU1MDwvYWNjZXNzaW9uLW51bT48dXJscz48cmVsYXRlZC11cmxzPjx1cmw+

aHR0cDovL3d3dy5uY2JpLm5sbS5uaWguZ292L3B1Ym1lZC8xOTc2MjU1MDwvdXJsPjx1cmw+aHR0

cDovL2pvdXJuYWwucHVibGljYXRpb25zLmNoZXN0bmV0Lm9yZy9kYXRhL0pvdXJuYWxzL0NIRVNU

LzIyMDgxL2NoZXN0LjA5LTE1ODQucGRmPC91cmw+PC9yZWxhdGVkLXVybHM+PC91cmxzPjxlbGVj

dHJvbmljLXJlc291cmNlLW51bT4xMC4xMzc4L2NoZXN0LjA5LTE1ODQ8L2VsZWN0cm9uaWMtcmVz

b3VyY2UtbnVtPjwvcmVjb3JkPjwvQ2l0ZT48L0VuZE5vdGU+AG==

ADDIN EN.CITE.DATA 25? Reflects bleeding risk in atrial fibrillation patients undergoing anticoagulant therapy, according to Pisters et al 2010PEVuZE5vdGU+PENpdGU+PEF1dGhvcj5QaXN0ZXJzPC9BdXRob3I+PFllYXI+MjAxMDwvWWVhcj48

UmVjTnVtPjk8L1JlY051bT48RGlzcGxheVRleHQ+PHN0eWxlIGZhY2U9InN1cGVyc2NyaXB0Ij4y

Njwvc3R5bGU+PC9EaXNwbGF5VGV4dD48cmVjb3JkPjxyZWMtbnVtYmVyPjk8L3JlYy1udW1iZXI+

PGZvcmVpZ24ta2V5cz48a2V5IGFwcD0iRU4iIGRiLWlkPSJ0ZXhwZWRkdG1mZWRwc2Vmd2ZvNWZ6

YWN3emE5YXZmcnhmZGEiIHRpbWVzdGFtcD0iMTQxNjU3MjgyMiI+OTwva2V5PjwvZm9yZWlnbi1r

ZXlzPjxyZWYtdHlwZSBuYW1lPSJKb3VybmFsIEFydGljbGUiPjE3PC9yZWYtdHlwZT48Y29udHJp

YnV0b3JzPjxhdXRob3JzPjxhdXRob3I+UGlzdGVycywgUi48L2F1dGhvcj48YXV0aG9yPkxhbmUs

IEQuIEEuPC9hdXRob3I+PGF1dGhvcj5OaWV1d2xhYXQsIFIuPC9hdXRob3I+PGF1dGhvcj5kZSBW

b3MsIEMuIEIuPC9hdXRob3I+PGF1dGhvcj5DcmlqbnMsIEguIEouPC9hdXRob3I+PGF1dGhvcj5M

aXAsIEcuIFkuPC9hdXRob3I+PC9hdXRob3JzPjwvY29udHJpYnV0b3JzPjxhdXRoLWFkZHJlc3M+

RGVwYXJ0bWVudCBvZiBDYXJkaW9sb2d5LCBNYWFzdHJpY2h0IFVuaXZlcnNpdHkgTWVkaWNhbCBD

ZW50cmUsIE1hYXN0cmljaHQsIFRoZSBOZXRoZXJsYW5kcy48L2F1dGgtYWRkcmVzcz48dGl0bGVz

Pjx0aXRsZT5BIG5vdmVsIHVzZXItZnJpZW5kbHkgc2NvcmUgKEhBUy1CTEVEKSB0byBhc3Nlc3Mg

MS15ZWFyIHJpc2sgb2YgbWFqb3IgYmxlZWRpbmcgaW4gcGF0aWVudHMgd2l0aCBhdHJpYWwgZmli

cmlsbGF0aW9uOiB0aGUgRXVybyBIZWFydCBTdXJ2ZXk8L3RpdGxlPjxzZWNvbmRhcnktdGl0bGU+

Q2hlc3Q8L3NlY29uZGFyeS10aXRsZT48YWx0LXRpdGxlPkNoZXN0PC9hbHQtdGl0bGU+PC90aXRs

ZXM+PHBlcmlvZGljYWw+PGZ1bGwtdGl0bGU+Q2hlc3Q8L2Z1bGwtdGl0bGU+PGFiYnItMT5DaGVz

dDwvYWJici0xPjwvcGVyaW9kaWNhbD48YWx0LXBlcmlvZGljYWw+PGZ1bGwtdGl0bGU+Q2hlc3Q8

L2Z1bGwtdGl0bGU+PGFiYnItMT5DaGVzdDwvYWJici0xPjwvYWx0LXBlcmlvZGljYWw+PHBhZ2Vz

PjEwOTMtMTAwPC9wYWdlcz48dm9sdW1lPjEzODwvdm9sdW1lPjxudW1iZXI+NTwvbnVtYmVyPjxr

ZXl3b3Jkcz48a2V5d29yZD5BZ2VkPC9rZXl3b3JkPjxrZXl3b3JkPkF0cmlhbCBGaWJyaWxsYXRp

b24vKmNvbXBsaWNhdGlvbnMvZXBpZGVtaW9sb2d5PC9rZXl3b3JkPjxrZXl3b3JkPkV1cm9wZS9l

cGlkZW1pb2xvZ3k8L2tleXdvcmQ+PGtleXdvcmQ+RmVtYWxlPC9rZXl3b3JkPjxrZXl3b3JkPkZp

YnJpbm9seXRpYyBBZ2VudHMvKmFkdmVyc2UgZWZmZWN0cy90aGVyYXBldXRpYyB1c2U8L2tleXdv

cmQ+PGtleXdvcmQ+Rm9sbG93LVVwIFN0dWRpZXM8L2tleXdvcmQ+PGtleXdvcmQ+SGVtb3JyaGFn

ZS8qZXBpZGVtaW9sb2d5L2V0aW9sb2d5PC9rZXl3b3JkPjxrZXl3b3JkPkh1bWFuczwva2V5d29y

ZD48a2V5d29yZD5JbmNpZGVuY2U8L2tleXdvcmQ+PGtleXdvcmQ+TWFsZTwva2V5d29yZD48a2V5

d29yZD5QbGF0ZWxldCBBZ2dyZWdhdGlvbiBJbmhpYml0b3JzLyphZHZlcnNlIGVmZmVjdHMvdGhl

cmFwZXV0aWMgdXNlPC9rZXl3b3JkPjxrZXl3b3JkPlBvcHVsYXRpb24gU3VydmVpbGxhbmNlLypt

ZXRob2RzPC9rZXl3b3JkPjxrZXl3b3JkPlByb2dub3Npczwva2V5d29yZD48a2V5d29yZD5Qcm9z

cGVjdGl2ZSBTdHVkaWVzPC9rZXl3b3JkPjxrZXl3b3JkPlJpc2sgQXNzZXNzbWVudC8qbWV0aG9k

czwva2V5d29yZD48a2V5d29yZD5SaXNrIEZhY3RvcnM8L2tleXdvcmQ+PGtleXdvcmQ+U3Ryb2tl

L2V0aW9sb2d5L3ByZXZlbnRpb24gJmFtcDsgY29udHJvbDwva2V5d29yZD48L2tleXdvcmRzPjxk

YXRlcz48eWVhcj4yMDEwPC95ZWFyPjxwdWItZGF0ZXM+PGRhdGU+Tm92PC9kYXRlPjwvcHViLWRh

dGVzPjwvZGF0ZXM+PGlzYm4+MTkzMS0zNTQzIChFbGVjdHJvbmljKSYjeEQ7MDAxMi0zNjkyIChM

aW5raW5nKTwvaXNibj48YWNjZXNzaW9uLW51bT4yMDI5OTYyMzwvYWNjZXNzaW9uLW51bT48dXJs

cz48cmVsYXRlZC11cmxzPjx1cmw+aHR0cDovL3d3dy5uY2JpLm5sbS5uaWguZ292L3B1Ym1lZC8y

MDI5OTYyMzwvdXJsPjwvcmVsYXRlZC11cmxzPjwvdXJscz48ZWxlY3Ryb25pYy1yZXNvdXJjZS1u

dW0+MTAuMTM3OC9jaGVzdC4xMC0wMTM0PC9lbGVjdHJvbmljLXJlc291cmNlLW51bT48L3JlY29y

ZD48L0NpdGU+PC9FbmROb3RlPn==

ADDIN EN.CITE PEVuZE5vdGU+PENpdGU+PEF1dGhvcj5QaXN0ZXJzPC9BdXRob3I+PFllYXI+MjAxMDwvWWVhcj48

UmVjTnVtPjk8L1JlY051bT48RGlzcGxheVRleHQ+PHN0eWxlIGZhY2U9InN1cGVyc2NyaXB0Ij4y

Njwvc3R5bGU+PC9EaXNwbGF5VGV4dD48cmVjb3JkPjxyZWMtbnVtYmVyPjk8L3JlYy1udW1iZXI+

PGZvcmVpZ24ta2V5cz48a2V5IGFwcD0iRU4iIGRiLWlkPSJ0ZXhwZWRkdG1mZWRwc2Vmd2ZvNWZ6

YWN3emE5YXZmcnhmZGEiIHRpbWVzdGFtcD0iMTQxNjU3MjgyMiI+OTwva2V5PjwvZm9yZWlnbi1r

ZXlzPjxyZWYtdHlwZSBuYW1lPSJKb3VybmFsIEFydGljbGUiPjE3PC9yZWYtdHlwZT48Y29udHJp

YnV0b3JzPjxhdXRob3JzPjxhdXRob3I+UGlzdGVycywgUi48L2F1dGhvcj48YXV0aG9yPkxhbmUs

IEQuIEEuPC9hdXRob3I+PGF1dGhvcj5OaWV1d2xhYXQsIFIuPC9hdXRob3I+PGF1dGhvcj5kZSBW

b3MsIEMuIEIuPC9hdXRob3I+PGF1dGhvcj5DcmlqbnMsIEguIEouPC9hdXRob3I+PGF1dGhvcj5M

aXAsIEcuIFkuPC9hdXRob3I+PC9hdXRob3JzPjwvY29udHJpYnV0b3JzPjxhdXRoLWFkZHJlc3M+

RGVwYXJ0bWVudCBvZiBDYXJkaW9sb2d5LCBNYWFzdHJpY2h0IFVuaXZlcnNpdHkgTWVkaWNhbCBD

ZW50cmUsIE1hYXN0cmljaHQsIFRoZSBOZXRoZXJsYW5kcy48L2F1dGgtYWRkcmVzcz48dGl0bGVz

Pjx0aXRsZT5BIG5vdmVsIHVzZXItZnJpZW5kbHkgc2NvcmUgKEhBUy1CTEVEKSB0byBhc3Nlc3Mg

MS15ZWFyIHJpc2sgb2YgbWFqb3IgYmxlZWRpbmcgaW4gcGF0aWVudHMgd2l0aCBhdHJpYWwgZmli

cmlsbGF0aW9uOiB0aGUgRXVybyBIZWFydCBTdXJ2ZXk8L3RpdGxlPjxzZWNvbmRhcnktdGl0bGU+

Q2hlc3Q8L3NlY29uZGFyeS10aXRsZT48YWx0LXRpdGxlPkNoZXN0PC9hbHQtdGl0bGU+PC90aXRs

ZXM+PHBlcmlvZGljYWw+PGZ1bGwtdGl0bGU+Q2hlc3Q8L2Z1bGwtdGl0bGU+PGFiYnItMT5DaGVz

dDwvYWJici0xPjwvcGVyaW9kaWNhbD48YWx0LXBlcmlvZGljYWw+PGZ1bGwtdGl0bGU+Q2hlc3Q8

L2Z1bGwtdGl0bGU+PGFiYnItMT5DaGVzdDwvYWJici0xPjwvYWx0LXBlcmlvZGljYWw+PHBhZ2Vz

PjEwOTMtMTAwPC9wYWdlcz48dm9sdW1lPjEzODwvdm9sdW1lPjxudW1iZXI+NTwvbnVtYmVyPjxr

ZXl3b3Jkcz48a2V5d29yZD5BZ2VkPC9rZXl3b3JkPjxrZXl3b3JkPkF0cmlhbCBGaWJyaWxsYXRp

b24vKmNvbXBsaWNhdGlvbnMvZXBpZGVtaW9sb2d5PC9rZXl3b3JkPjxrZXl3b3JkPkV1cm9wZS9l

cGlkZW1pb2xvZ3k8L2tleXdvcmQ+PGtleXdvcmQ+RmVtYWxlPC9rZXl3b3JkPjxrZXl3b3JkPkZp

YnJpbm9seXRpYyBBZ2VudHMvKmFkdmVyc2UgZWZmZWN0cy90aGVyYXBldXRpYyB1c2U8L2tleXdv

cmQ+PGtleXdvcmQ+Rm9sbG93LVVwIFN0dWRpZXM8L2tleXdvcmQ+PGtleXdvcmQ+SGVtb3JyaGFn

ZS8qZXBpZGVtaW9sb2d5L2V0aW9sb2d5PC9rZXl3b3JkPjxrZXl3b3JkPkh1bWFuczwva2V5d29y

ZD48a2V5d29yZD5JbmNpZGVuY2U8L2tleXdvcmQ+PGtleXdvcmQ+TWFsZTwva2V5d29yZD48a2V5

d29yZD5QbGF0ZWxldCBBZ2dyZWdhdGlvbiBJbmhpYml0b3JzLyphZHZlcnNlIGVmZmVjdHMvdGhl

cmFwZXV0aWMgdXNlPC9rZXl3b3JkPjxrZXl3b3JkPlBvcHVsYXRpb24gU3VydmVpbGxhbmNlLypt

ZXRob2RzPC9rZXl3b3JkPjxrZXl3b3JkPlByb2dub3Npczwva2V5d29yZD48a2V5d29yZD5Qcm9z

cGVjdGl2ZSBTdHVkaWVzPC9rZXl3b3JkPjxrZXl3b3JkPlJpc2sgQXNzZXNzbWVudC8qbWV0aG9k

czwva2V5d29yZD48a2V5d29yZD5SaXNrIEZhY3RvcnM8L2tleXdvcmQ+PGtleXdvcmQ+U3Ryb2tl

L2V0aW9sb2d5L3ByZXZlbnRpb24gJmFtcDsgY29udHJvbDwva2V5d29yZD48L2tleXdvcmRzPjxk

YXRlcz48eWVhcj4yMDEwPC95ZWFyPjxwdWItZGF0ZXM+PGRhdGU+Tm92PC9kYXRlPjwvcHViLWRh

dGVzPjwvZGF0ZXM+PGlzYm4+MTkzMS0zNTQzIChFbGVjdHJvbmljKSYjeEQ7MDAxMi0zNjkyIChM

aW5raW5nKTwvaXNibj48YWNjZXNzaW9uLW51bT4yMDI5OTYyMzwvYWNjZXNzaW9uLW51bT48dXJs

cz48cmVsYXRlZC11cmxzPjx1cmw+aHR0cDovL3d3dy5uY2JpLm5sbS5uaWguZ292L3B1Ym1lZC8y

MDI5OTYyMzwvdXJsPjwvcmVsYXRlZC11cmxzPjwvdXJscz48ZWxlY3Ryb25pYy1yZXNvdXJjZS1u

dW0+MTAuMTM3OC9jaGVzdC4xMC0wMTM0PC9lbGVjdHJvbmljLXJlc291cmNlLW51bT48L3JlY29y

ZD48L0NpdGU+PC9FbmROb3RlPn==

ADDIN EN.CITE.DATA 26Supplemental table SEQ Supplemental_table \* ARABIC 2: Other anticoagulants specified according to ATC codesDrug groupSpecific drugVitamin K-antagonistB01AA04 phenprocumonB01AA07 acenocoumarolHeparin groupB01AB01 heparinB01AB02 antithrombin IIIB01AB04 dalteparinB01AB05 enoxaparinB01AB09 danaparoidB01AB10 tinzaparinPlatelet aggregation inhibitors excl. heparinB01AC04 clopidogrelB01AC05 ticlopidineB01AC06 acetylsalicylic acidB01AC07 dipyridamoleB01AC09 epoprostenolB01AC11 iloprostB01AC21 treprostinilB01AC22 prasugrelB01AC24 ticagrelorB01AC30 combinationsEnzymesB01AD01 streptokinaseB01AD02 alteplaseB01AD10 drotrecogin alfaDirect thrombin inhibitorsB01AE02 lepirudinB01AE03 argatrobanB01AE05 ximelagatranOther antithrombotic agentsB01AX05 fondaparinuxSupplemental table SEQ Supplemental_table \* ARABIC 3: Definition of covariates according to International Classification of Diseases 10th version codes and the Anatomic Therapeutic Chemical classification system.CovariatesICD 10 / ATC codesCongestive heart failureI110, I130, I132, I420, I50 or ATC C03CVascular diseaseI21-I22, I700, I702-I709Ischemic stroke I63, I64EmbolismI26, I74Transient ischemic attack (TIA) G45Peripheral arterial disease I702-I709, I71, I739Myocardial infarctionI21-I23Abnormal renal function Hypertensive renal disease: I12, I13Glomerular diseases: N00-N05, N07 Renal tubulo-interstitial diseases N11, N14 Renal failure N17-N19Cystic kidney disease Q61Abnormal hepatic function Hepatitis with hepatic coma: B150, B160, B162, B190, Esophageal varices I85Hepatic failure K704, K72Portal hypertension K766Alcohol relatedE244, E529A, F10, G312, G621, G721, I426, K292, K70, K860, L278A, O354M, T51, Z714, Z721DiabetesE10-E14 or ATC: A10 HypertensionI10-I15 orcombination treatment with at least two of the following classes of antihypertensive drugs:I. Alpha adrenergic blockers (C02A, C02B, C02C)II. Non-loop diuretics (C02DA, C02L, C03A, C03B, C03D, C03E, C03X, C07C, C07D, C08G, C09BA, C09DA, C09XA52)III. Vasodilators (C02DB, C02DD, C02DG, C04, C05)IV. Beta blockers (C07)V. Calcium channel blockers (C07F, C08, C09BB, C09DB)VI. Renin-angiotensin system inhibitors (C09)Renal diseaseDiabetes mellitus with renal complications: E102, E112, E132, E142Hypertensive renal disease with renal failure: I120Systemic connective tissue disorders with renal involvement: M300, M313, M321BGlomerular diseases: N02-N08, Renal tubulo-interstitial diseases: N11-N12, N14, N158-N160, N162-N164, N168, Chronic kidney disease/failure/contraction: N18-N19, N26, Cystic kidney disease: Q612-Q613, Q615, Q619Anuria and oliguria R34 Dialysis/kidney transplant: Z49, Z940Procedure codes for dialysis: DR015-DR016, DR023-DR024, DR055-DR056Surgical code for kidney transplant: KASHepatic diseaseB15-B19, C22, D684C, I982B, K70-K77, R16, R17, Z944 Surgical code: JJCDisorders of thyroid glandE00-E07Low dose acetylsalicylic acidB01AC06ClopidogrelB01AC04AntidepressantsN06AB, N06AX21, N06AX16AntibioticsJ04AB02, J01FA09AntiarrhythmicsC01BD01, C01BD07, C08DA01Non-steroidal anti-inflammatoryM01AAntimycoticsD01AC08, J02AC02, J02AC04SteroidsH02ASupplemental table SEQ Supplemental_table \* ARABIC 4: Definition of studied outcomes according to ICD 10 codesOutcomesTextICD 10Other BleedingAcute posthaemorrhagic anaemiaD62 Haemorrhagic disorder due to circulating anticoagulantsD683Haemorrhagic condition, unspecifiedD699Conjunctival haemorrhageH113Choroidal haemorrhage and ruptureH313Retinal haemorrhageH356Vitreous haemorrhageH431Vitreous haemorrhage in diseases classified elsewhereH450OtorrhagiaH922Oesophageal varices with bleedingI850Oesophageal varices with bleeding in diseases classified elsewhereI983HaemothoraxJ942Gastro-oesophageal laceration-haemorrhage syndromeK226Other specified diseases of oesophagus (Haemorrhage of oesophagus NOS)K228Gastric ulcer Chronic or unspecified with haemorrhageK254Gastric ulcer Chronic or unspecified with both haemorrhage and perforationK256Duodenal ulcer Chronic or unspecified with haemorrhageK264Duodenal ulcer Chronic or unspecified with both haemorrhage and perforationK266Peptic ulcer, site unspecified Chronic or unspecified with haemorrhageK274Peptic ulcer, site unspecified Chronic or unspecified with both haemorrhage and perforationK276Gastrojejunal ulcer Chronic or unspecified with haemorrhageK284Gastrojejunal ulcer Chronic or unspecified with both haemorrhage and perforationK286Haemorrhage of anus and rectumK625HaemoperitoneumK661Recurrent and persistent haematuriaN02Vascular disorders of male genital organs (Haematocele NOS, Haemorrhage, Thrombosis)N501Haemorrhage from respiratory passagesR04Spontaneous ecchymosesR233Unspecified haematuriaR31Haemorrhage, not elsewhere classifieR58Other intracranial injuriesS068DeathAll-cause mortalityN/AGastro-intestinal bleedingGastric ulcer Acute with hemorrhageK250Gastric ulcer Acute with both hemorrhage and perforationK252Duodenal ulcer Acute with hemorrhageK260Duodenal ulcer Acute with both hemorrhage and perforationK262Peptic ulcer, site unspecified Acute with hemorrhageK270Peptic ulcer, site unspecified Acute with both hemorrhage and perforationK272Gastrojejunal ulcer Acute with hemorrhageK280Gastrojejunal ulcer Acute with both hemorrhage and perforationK282Acute hemorrhagic gastritisK290HematemesisK920MelaenaK921Gastrointestinal hemorrhage, unspecifiedK922Intracranial bleedingSubarachnoid haemorrhageI60Intracerebral haemorrhageI61Other nontraumatic intracranial haemorrhageI62Sequelae of subarachnoid haemorrhageI690Sequelae of intracerebral haemorrhageI691Sequelae of other nontraumatic intracranial haemorrhageI692Epidural haemorrhageS064Traumatic subdural haemorrhageS065Traumatic subarachnoid haemorrhageS066Supplemental table SEQ Supplemental_table \* ARABIC 5: Standardized difference as the differences in means between each pair of treatment groups divided by the standard deviation, before and after propensity scoreVariableDTI vs VKAXAB vs DTIXAB vs VKABeforeAfterBeforeAfterBeforeAfterAbnormal hepatic function0.19-0.01-0.100.020.09-0.01Abnormal renal function0.020.01-0.01-0.010.01-0.02Age <75-0.310.000.290.00-0.020.01Age 75-790.06-0.01-0.04-0.020.02-0.01Age 80-840.170.00-0.110.030.06-0.01Age 85 +0.220.01-0.27-0.01-0.060.00Alcohol related-0.050.010.050.00-0.01-0.01Antiarrhythmics0.090.01-0.04-0.010.050.02Antibiotics0.010.02-0.010.020.000.01Antidepressants0.020.01-0.04-0.01-0.02-0.01Antimycotics-0.02-0.030.010.03-0.01-0.03Bleeding0.030.00-0.06-0.01-0.040.00CHA2DS2VASc score >70.050.01-0.05-0.010.000.01CHA2DS2VASc score 0-1-0.230.000.170.01-0.050.01CHA2DS2VASc score 2-3-0.13-0.010.08-0.02-0.04-0.01CHA2DS2VASc score 4-70.290.01-0.210.010.080.00Clopidogrel0.07-0.01-0.06-0.010.010.00Congestive heart failure0.190.01-0.090.010.10-0.01County Blekinge0.09-0.01-0.100.000.00-0.02County Dalarna0.040.02-0.110.03-0.070.00County G?vleborg0.18-0.01-0.030.020.150.01County Gotland0.130.00-0.080.010.070.02County Halland-0.310.020.20-0.01-0.12-0.01County J?mtland0.13-0.01-0.090.010.040.00County J?nk?ping0.150.00-0.19-0.01-0.04-0.03County Kalmar0.130.01-0.100.010.030.00County Kronoberg0.180.00-0.200.01-0.030.02County Norrbotten0.180.00-0.100.010.09-0.02County ?rebro0.190.00-0.180.020.000.01County ?sterg?tland0.230.00-0.24-0.01-0.01-0.02County Sk?ne-0.19-0.020.19-0.04-0.010.02County S?dermanland0.04-0.010.00-0.010.040.01County Stockholm-0.340.000.33-0.01-0.010.02County Uppsala-0.030.010.000.02-0.030.00County V?rmland-0.310.020.220.04-0.10-0.02County V?sterbotten0.17-0.01-0.100.020.070.00County V?sternorrland0.21-0.01-0.08-0.020.130.01County V?stmanland-0.210.02-0.01-0.03-0.22-0.02County V?stra g?taland0.330.00-0.300.020.03-0.02Diabetes0.11-0.01-0.050.000.060.00Disorders of thyroid gland0.020.00-0.030.01-0.010.00Education 9-year compulsory school0.20-0.01-0.120.020.08-0.01Education High school0.020.02-0.01-0.010.01-0.02Education missing0.010.01-0.01-0.020.000.02Education Tertiary education-0.24-0.020.140.00-0.100.02Embolism0.030.02-0.010.010.01-0.01Female0.080.00-0.100.01-0.020.00Fenproc-0.02-0.030.010.00-0.010.00HAS-BLED score >50.030.00-0.030.010.00-0.01HAS-BLED score 0-0.110.000.09-0.01-0.020.00HAS-BLED score 1-3-0.050.000.040.01-0.020.01HAS-BLED score 4-50.120.00-0.090.000.03-0.01Hepatic disease0.010.000.000.000.01-0.02Home support0.07-0.02-0.160.01-0.090.00Home support hours/week >900.04-0.01-0.080.01-0.04-0.01Home support hours/week 0-0.070.020.16-0.010.090.00Home support hours/week 1-440.04-0.01-0.09-0.01-0.050.00Home support hours/week 45-890.05-0.01-0.100.02-0.060.01Hospitalization days >90.100.01-0.100.02-0.010.00Hospitalization days 0-0.17-0.020.090.01-0.080.01Hospitalization days 1-30.080.02-0.010.000.070.00Hospitalization days 4-90.130.01-0.09-0.030.04-0.01Hypertension0.160.01-0.090.020.070.01Ischemic stroke0.06-0.02-0.060.010.00-0.01Non-na?ve0.160.010.00-0.020.160.01Non-steroidal anti-inflammatory-0.05-0.010.040.01-0.010.00Number drugs <=5-0.220.000.17-0.03-0.050.00Number drugs >50.220.00-0.170.030.050.00Nursing home0.060.01-0.12-0.01-0.060.00Outpatient visits >9-0.010.010.080.010.070.00Outpatient visits 0-0.13-0.02-0.610.00-0.750.01Outpatient visits 1-30.130.020.500.000.65-0.01Outpatient visits 4-9-0.010.000.220.000.220.01Peripheral arterial disease0.090.01-0.05-0.030.030.00Platelet inhibitors0.110.010.040.000.150.00Private clinic-0.25-0.010.19-0.01-0.08-0.01Renal disease0.19-0.01-0.090.020.10-0.01Short-term housing0.040.03-0.09-0.01-0.050.00Steroids0.060.00-0.07-0.03-0.010.01Time period 2012 Q1 0.290.010.230.000.450.00Time period 2012 Q2 0.220.020.260.000.430.00Time period 2012 Q3 0.230.010.230.000.410.00Time period 2012 Q4 0.14-0.010.29-0.010.400.01Time period 2013 Q1 0.110.030.300.010.390.01Time period 2013 Q2 0.070.000.310.010.370.01Time period 2013 Q3 0.06-0.010.270.010.32-0.01Time period 2013 Q4 -0.02-0.010.290.000.27-0.01Time period 2014 Q1 0.010.010.17-0.020.180.01Time period 2014 Q2 -0.090.000.13-0.010.040.00Time period 2014 Q3 -0.14-0.010.130.02-0.01-0.02Time period 2014 Q4 -0.120.000.010.00-0.11-0.05Time period 2015 Q1 -0.100.00-0.11-0.03-0.200.01Time period 2015 Q2 -0.08-0.02-0.21-0.02-0.29-0.02Time period 2015 Q3 -0.010.00-0.290.01-0.290.00Time period 2015 Q4 -0.080.00-0.320.01-0.390.01Time period 2016 Q1 -0.210.00-0.190.01-0.390.00Time period 2016 Q2 -0.20-0.02-0.250.00-0.420.01Time period 2016 Q3 -0.220.00-0.240.01-0.430.03Time period 2016 Q4 -0.200.01-0.19-0.01-0.360.00Transient ischemic attack (TIA)0.060.00-0.050.010.010.01Urban city living0.100.000.450.010.55-0.03Vascular disease0.140.01-0.09-0.010.050.001: DTI = direct thrombin inhibitors, VKA = vitamin K antagonists, XAB = direct factor Xa inhibitorsSupplemental table SEQ Supplemental_table \* ARABIC 6: Hazard ratios with 95% confidence intervals, for each outcome and comparison, by sex. All patients were 60 years of age or older and with a diagnosis of atrial fibrillation within 6 months before start of treatment with direct thrombin inhibitors, direct factor Xa inhibitors or with vitamin K antagonistsComparison1MenWomenBleedingsDTI vs. VKA0.86?(0.65, 1.12)0.93?(0.66, 1.31)XAB vs. VKA0.95?(0.76, 1.19)1.21?(0.94, 1.56)XAB vs. DTI1.12?(0.84, 1.52)1.26?(0.89, 1.81)GastrointestinalDTI vs. VKA0.73?(0.40, 1.30)2.41?(1.31, 4.74) 2XAB vs. VKA0.78?(0.51, 1.20)1.38?(0.89, 2.17)XAB vs. DTI1.00?(0.55, 1.81)0.69?(0.39, 1.18)IntracranialDTI vs. VKA0.69?(0.33, 1.44)0.51?(0.19, 1.30)XAB vs. VKA0.67?(0.38, 1.16)0.88?(0.51, 1.54)XAB vs. DTI1.39?(0.55, 3.78)1.78?(0.64, 5.65)DeathDTI vs. VKA1.29?(0.79, 2.14)1.78?(0.98, 3.40)XAB vs. VKA1.66?(1.21, 2.30)21.60?(1.16, 2.25) 2XAB vs. DTI1.12?(0.71, 1.76)1.45?(0.90, 2.36)1: DTI = direct thrombin inhibitors, VKA = vitamin K antagonists, XAB = direct factor Xa inhibitors2: Statistically significant at the 5% significance levelSupplemental table SEQ Supplemental_table \* ARABIC 7: Hazard ratios with 95% confidence intervals, for each outcome and comparison, by age. All patients were 60 years of age or older and with a diagnosis of atrial fibrillation within 6 months before start of treatment with direct thrombin inhibitors, direct factor Xa inhibitors or with vitamin K antagonistsComparison160-7475-7980-8485+BleedingsDTI vs. VKA0.71 (0.53, 0.95)1.16 (0.76, 1.80)1.09 (0.59, 2.04)0.98 (0.49, 1.97)XAB vs. VKA0.83 (0.64, 1.09)1.15 (0.80, 1.65)1.99 (1.30, 3.14) 21.03 (0.72, 1.48)XAB vs. DTI1.05 (0.74, 1.49)1.18 (0.76, 1.86)1.39 (0.80, 2.47)1.62 (0.83, 3.29)GastrointestinalDTI vs. VKA1.14 (0.66, 2.00)1.22 (0.55, 2.83)1.70 (0.53, 6.41)0.89 (0.24, 3.40)XAB vs. VKA0.78 (0.45, 1.35)1.34 (0.66, 2.83)1.92 (0.88, 4.65)1.03 (0.57, 1.89)XAB vs. DTI0.61 (0.32, 1.13)1.16 (0.53, 2.56)0.61 (0.20, 1.77)1.86 (0.58, 7.03)IntracranialDTI vs. VKA0.45 (0.18, 1.05)0.70 (0.22, 2.15)0.54 (0.07, 3.28)1.10 (0.18, 8.43)XAB vs. VKA0.63 (0.33, 1.18)0.86 (0.38, 1.98)2.21 (0.84, 6.85)0.76 (0.33, 1.76)XAB vs. DTI1.49 (0.36, 7.27)0.91 (0.28, 3.02)2.34 (0.49, 17.17)0.53 (0.02, 5.60)DeathDTI vs. VKA2.66 (1.31, 5.99) 21.00 (0.49, 2.09)1.51 (0.52, 4.96)1.73 (0.79, 4.06)XAB vs. VKA1.48 (0.93, 2.42)1.30 (0.76, 2.30)1.52 (0.94, 2.52)1.89 (1.32, 2.75)XAB vs. DTI0.79 (0.43, 1.46)0.72 (0.32, 1.55)2.93 (1.33, 7.38) 21.65 (0.90, 3.18)1: DTI = direct thrombin inhibitors, VKA = vitamin K antagonists, XAB = direct factor Xa inhibitors2: Statistically significant at the 5% significance levelSupplemental table SEQ Supplemental_table \* ARABIC 8: Hazard ratios with 95% confidence intervals, for each outcome and comparison, by user status. All patients were 60 years of age or older and with a diagnosis of atrial fibrillation within 6 months before start of treatment with direct thrombin inhibitors, direct factor Xa inhibitors or with vitamin K antagonistsComparison1Na?veNon-na?veBleedingsDTI vs. VKA0.78 (0.56, 1.07)1.01 (0.75, 1.35)XAB vs. VKA0.97 (0.75, 1.27)1.12 (0.90, 1.40)XAB vs. DTI1.33 (0.94, 1.90)1.10 (0.81, 1.50)GastrointestinalDTI vs. VKA1.24 (0.67, 2.31)1.27 (0.75, 2.19)XAB vs. VKA1.05 (0.64, 1.74)1.28 (0.84, 1.96)XAB vs. DTI0.76 (0.41, 1.40)0.70 (0.39, 1.24)IntracranialDTI vs. VKA0.48 (0.20, 1.04)1.02 (0.35, 3.12)XAB vs. VKA0.55 (0.29, 1.00)1.09 (0.63, 1.91)XAB vs. DTI0.99 (0.35, 2.82)5.05 (1.69, 21.66)2DeathDTI vs. VKA1.90 (1.02, 3.70)21.28 (0.79, 2.10)XAB vs. VKA1.39 (0.96, 2.04)1.79 (1.35, 2.38)2XAB vs. DTI0.92 (0.55, 1.54)1.36 (0.87, 2.15)1: DTI = direct thrombin inhibitors, VKA = vitamin K antagonists, XAB = direct factor Xa inhibitors2: Statistically significant at the 5% significance level ................
................

In order to avoid copyright disputes, this page is only a partial summary.

Google Online Preview   Download